Aimmune Therapeutics (AIMT) PT Raised to $45 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Aimmune Therapeutics (AIMT) Prices 5.5M Share Common Offering at $32/Sh
February 22, 2018 5:54 AM ESTAimmune Therapeutics, Inc. (NASDAQ: AIMT) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Aimmune. All of... More
DBV Technologies (DBVT) on Watch After Competitor Reports Positive Data for Patients With Peanut Allergy
February 20, 2018 7:24 AM ESTDBV Technologies (NASDAQ: DBVT) was in focus Tuesday morning after competitor Aimmune Therapeutics, Inc. (Nasdaq: AIMT) announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the primary endpoint. AR101 has U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for peanut-allergic patients ages 417.
... MoreAimmune Therapeutics (AIMT) to Resume Trading at 7:30 am ET
February 20, 2018 7:07 AM ESTAimmune Therapeutics (NASDAQ: AIMT) to Resume Trading at 7:30 am ET
... MoreAimmune Therapeutics (AIMT) Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
February 20, 2018 7:00 AM ESTAimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the primary endpoint. In the United States, AR101 has U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation... More
